FBRX beat EPS expectations by 26.55%
Apr 08, 2025, 10:32 AM
0.00%
What does FBRX do
Forte Biosciences, a Dallas-based biopharmaceutical company, specializes in dermatology products and is advancing product candidate FB-102 for autoimmune diseases. The company went public on April 13, 2017, and holds a U.S. patent for skin treatment.
Forte Biosciences (FBRX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Forte Biosciences's actual EPS was -$2.45, beating the estimate of -$3.34 per share, resulting in a 26.55% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.